These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34940082)

  • 21. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
    Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
    Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis.
    Ismail MD; Wiratnaya IGE; Raditya RH
    Asian Pac J Cancer Prev; 2024 May; 25(5):1497-1505. PubMed ID: 38809621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).
    Palmerini E; Meazza C; Tamburini A; Bisogno G; Ferraresi V; Asaftei SD; Milano GM; Coccoli L; Manzitti C; Luksch R; Serra M; Gambarotti M; Donati DM; Scotlandi K; Bertulli R; Favre C; Longhi A; Abate ME; Perrotta S; Mascarin M; D'Angelo P; Cesari M; Staals EL; Marchesi E; Carretta E; Ibrahim T; Casali PG; Picci P; Fagioli F; Ferrari S
    Cancer; 2022 May; 128(10):1958-1966. PubMed ID: 35201621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
    Kushnir I; Kolander Y; Bickels J; Gortzak Y; Flusser G; Issakov J; Merimsky O
    Med Oncol; 2014 May; 31(5):936. PubMed ID: 24719037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
    Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
    Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique.
    Philip T; Iliescu C; Demaille MC; Pacquement H; Gentet JC; Krakowski I; Soler-Michel P; Thiesse P; Chauvin F; Blay JY; Brunat-Mentigny M
    Ann Oncol; 1999 Sep; 10(9):1065-71. PubMed ID: 10572604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
    Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
    J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Osteosarcoma in Children Without High-Dose Methotrexate: Could It Be Less Toxic Without Effecting Survival Rates?
    Eker N; Tokuc AG; Yılmaz B; Aktaş Z; Buğdaycı O; Erol B; Senay E; Aras S
    J Adolesc Young Adult Oncol; 2022 Jun; 11(3):252-258. PubMed ID: 34342492
    [No Abstract]   [Full Text] [Related]  

  • 38. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.
    Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
    J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.